Evidence map›Paper›PMID 37250921›Full record

ArticleOncoimmunology2023

T-cell dysfunction in natural killer/T-cell lymphoma.

Xiaoyan Feng, Miaomiao Meng, Hongwen Li, Yuyang Gao, Wenting Song, Ruiqing Di, Zhaoming Li, Xudong Zhang, Mingzhi Zhang

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. CD8Frontiers in immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiaoyan FengDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Miaomiao MengDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hongwen LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuyang GaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wenting SongDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ruiqing DiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhaoming LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xudong ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer/T-cell lymphoma (NKTCL) is an incurable aggressive T-cell lymphoma closely correlated with Epstein‒Barr virus (EBV) infection. Chronic and consistent viral infection induces T-cell exhaustion. Herein, we describe T-cell dysfunction in NKTCL patients for the first time. Peripheral blood mononuclear cells (PBMCs) from age-matched healthy donors (HDs) and NKTCL patients were collected, and lymphocyte distributions, multiple surface inhibitory receptors (IRs), effector cytokine production and cell proliferation were determined by flow cytometry. PBMCs from HDs were cocultured with NKTCL cell lines to verify the clinical findings. IR expression was further assessed in NKTCL tumor biopsies using multiplex immunohistochemistry (mIHC). NKTCL patients have higher frequencies than HDs of inhibitory T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). T-cell distribution also varies between NKTCL patients and HDs. T cells from NKTCL patients demonstrated higher expression levels of multiple IRs than HDs. Meanwhile, T-cell proliferation and interferon-γ production was significantly reduced in NKTCL patients. More importantly, the number of EBV-specific cytotoxic cells was lower in NTKCL patients, and these cells demonstrated upregulation of multiple IRs and secreted fewer effector cytokines. Interestingly, NKTCL cells caused normal PBMCs to acquire T-cell exhaustion phenotypes and induced generation of Tregs and MDSCs. In line with ex vivo finding, mIHC results showed that CD8+ T cells from NKTCL tumor biopsies expressed much higher level of IRs compared with reactive lymphoid hyperplasia individuals. The immune microenvironment of NKTCL patients exhibited T-cell dysfunction and accumulation of inhibitory cell components, which may contribute to impaired antitumor immunity.

Indexed as

Epstein-Barr Virus InfectionsLymphoma, Extranodal NK-T-CellHerpesvirus 4, HumanHumansKiller Cells, NaturalLeukocytes, MononuclearTumor MicroenvironmentEpstein‒Barr virusinhibitory receptorsNK/T-cell lymphomaT-cell exhaustion

Identifiers

PMID37250921
PMCPMC10210841
OpenAlexW4378071564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.